Erratum to: Methods for evaluating medical tests and biomarkers

[This corrects the article DOI: 10.1186/s41512-016-0001-y.]

Evidence synthesis to inform model-based cost-effectiveness evaluations of diagnostic tests: a methodological systematic review of health technology assessments

Background: Evaluations of diagnostic tests are challenging because of the indirect nature of their impact on patient outcomes. Model-based health economic evaluations of tests allow different types of evidence from various sources to be incorporated and enable cost-effectiveness estimates to be made beyond the duration of available study data. To parameterize a health-economic model fully, all the ways a test impacts on patient health must be quantified, including but not limited to diagnostic test accuracy. Methods: We assessed all UK NIHR HTA reports published May 2009-July 2015. Reports were included if they evaluated a diagnostic test, included a model-based health economic evaluation and included a systematic review and meta-analysis of test accuracy. From each eligible report we extracted information on the following topics: 1) what evidence aside from test accuracy was searched for and synthesised, 2) which methods were used to synthesise test accuracy evidence and how did the results inform the economic model, 3) how/whether threshold effects were explored, 4) how the potential dependency between multiple tests in a pathway was accounted for, and 5) for evaluations of tests targeted at the primary care setting, how evidence from differing healthcare settings was incorporated. Results: The bivariate or HSROC model was implemented in 20/22 reports that met all inclusion criteria. Test accuracy data for health economic modelling was obtained from meta-analyses completely in four reports, partially in fourteen reports and not at all in four reports. Only 2/7 reports that used a quantitative test gave clear threshold recommendations. All 22 reports explored the effect of uncertainty in accuracy parameters but most of those that used multiple tests did not allow for dependence between test results. 7/22 tests were potentially suitable for primary care but the majority found limited evidence on test accuracy in primary care settings. Conclusions: The uptake of appropriate meta-analysis methods for synthesising evidence on diagnostic test accuracy in UK NIHR HTAs has improved in recent years. Future research should focus on other evidence requirements for cost-effectiveness assessment, threshold effects for quantitative tests and the impact of multiple diagnostic tests

Erratum to: Methods for evaluating medical tests and biomarkers

[This corrects the article DOI: 10.1186/s41512-016-0001-y.]

Patterned-ground plant communities along a bioclimate gradient in the High Arctic, Canada

Non-sorted circles, non-sorted polygons, and earth hummocks are common ground-surface features ill arctic regions. The), are caused by a variety of physical processes that Occur in permafrost regions including contraction cracking and frost heave. Here we describe the vegetation of patterned-ground forms on zonal sites at three location!: along an N-S transect through the High Arctic of Canada. We made 75 releves on patterned-ground features (circles, polygons, earth hummocks) and adjacent tundra (Interpolygon, intercircle, interhummock areas) and identified and classified the vegetation according to the Braun-Blanquet Method. Environmental factors were correlated with the vegetation data using a nonmetric multidimensional scaling ordination (NMDS). We identified eleven commnunities: (1) Puccinellia angustata-Papaver radicalum community in xeromesic non-sorted polygons of subzone A of the Circumpolar Arctic Vegetation Map; (2) Saxifraga-Parmelia omphalodes ssp. glacialis community in hydromesic interpolygon areas of subzone A; (3) Hypogymnia subobscura-Lecanora epibryon community In xeromesic non-sorted polygons of subzone B; (4) Orthotrichum speciosum-Salix arctica community In xeromesic interpolygon areas of subzone B; (5) Cochlearia groenlandica-Luzula nivalis community in hydromesic earth Mocks Of subzone B; (6) Salix arctica-Eriophorum angustifolium ssp. triste community in hygric earth hummocks of subzone 13; (7) Puccinellia angustata-Potentilla vahliana community in xeromesic non-sorted circles and bare patches of subzone Q (8) Dryas integrifolia-Carex rupestris community in xeromesic intercircle areas and vegetated patches of subzone C; (9) Braya glabella ssp. purpurascens-Dryas integrifolia community In hydromesic non-sorted circles of subzone Q (10) Dryas integrifolia-Carex aquatilis community in hydromesic intercircle areas of subzone C; and (11) Eriophorum angustifolium ssp. triste-Carex aquatilis community ill hygric intercircle areas of subzone C. The NMDS ordination displayed the vegetation types with respect to complex environmental gradients. The first axis of the ordination corresponds to a complex soil moisture gradient and the second axis corresponds to a complex geology/elevation/climate gradient. The tundra plots have a greater moss and graminoid cover than the adjacent frost-heave communities. In general, frost-heave features have greater thaw depths, more bare ground, thinner organic horizons, and lower soil moisture than the surrounding tundra. The morphology of the investigated patterned ground forms changes along the climatic gradient, with non-sorted pollygons dominating in the northernmost sites and non-sorted circles dominating, in the southern sites

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Contains fulltext : 118365.pdf (publisher's version ) (Closed access)BACKGROUND: Until now, only imatinib and sunitinib have proven clinical benefit in patients with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in fatal disease progression. We aimed to assess efficacy and safety of regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least imatinib and sunitinib. METHODS: We did this phase 3 trial at 57 hospitals in 17 countries. Patients with histologically confirmed, metastatic or unresectable GIST, with failure of at least previous imatinib and sunitinib were randomised in a 2:1 ratio (by computer-generated randomisation list and interactive voice response system; preallocated block design (block size 12); stratified by treatment line and geographical region) to receive either oral regorafenib 160 mg daily or placebo, plus best supportive care in both groups, for the first 3 weeks of each 4 week cycle. The study sponsor, participants, and investigators were masked to treatment assignment. The primary endpoint was progression-free survival (PFS). At disease progression, patients assigned placebo could crossover to open-label regorafenib. Analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01271712. RESULTS: From Jan 4, to Aug 18, 2011, 240 patients were screened and 199 were randomised to receive regorafenib (n=133) or matching placebo (n=66). Data cutoff was Jan 26, 2012. Median PFS per independent blinded central review was 4.8 months (IQR 1.4-9.2) for regorafenib and 0.9 months (0.9-1.8) for placebo (hazard ratio [HR] 0.27, 95% CI 0.19-0.39; p<0.0001). After progression, 56 patients (85%) assigned placebo crossed over to regorafenib. Drug-related adverse events were reported in 130 (98%) patients assigned regorafenib and 45 (68%) patients assigned placebo. The most common regorafenib-related adverse events of grade 3 or higher were hypertension (31 of 132, 23%), hand-foot skin reaction (26 of 132, 20%), and diarrhoea (seven of 132, 5%). INTERPRETATION: The results of this study show that oral regorafenib can provide a significant improvement in progression-free survival compared with placebo in patients with metastatic GIST after progression on standard treatments. As far as we are aware, this is the first clinical trial to show benefit from a kinase inhibitor in this highly refractory population of patients. FUNDING: Bayer HealthCare Pharmaceuticals

Erratum to: Methods for evaluating medical tests and biomarkers

The original MEMTAB Abstracts in Diagnostic and Prognostic Research contains the incorrect year on individual abstracts in the PDF [1].“Diagnostic and Prognostic Research 2016” under the correspondence line should therefore have been written as “Diagnostic and Prognostic Research 2017” as the journal did not launch until 2017